You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Investigators reported that the classifier could correctly predict cancer type with over 94 percent accuracy and highlighted impacts in a commercially tested cohort.
The ImmunArray spinoff said the financing will go toward a clinical trial and submission to FDA for its traumatic brain injury test.
The firm said that its AI-based breast cancer detection software, Paige Breast, draws a pathologist's attention to concerning features on a breast tissue slide.
The companies aim to create new products enabling faster access to predictive information used in treatment planning for patients with breast cancer.
The company also announced John Leite, the former leader of clinical business development activities at Illumina, had joined the firm as chief business officer.
The company recently received FDA Emergency Use Authorization for its SARS-CoV-2 PCR test while its data-driven COVID-19 research initiative is moving along.
The project, coordinated by Jena University Hospital and expected to run for five years, aims to address resistance mechanisms in Gram-negative pathogens.
The company's mobile app provides automated COVID-19 screening and directs potential patients to testing locations for confirmatory testing.
Cernostics offers an assay that analyzes whole-slide digital images with multiplexed fluorescence to help interpret Barrett's esophagus patient biopsies.
The firm said the financing enables it to progress with the development of an algorithm that would help detect the most common cancers.